Compare abrdn Income Credit Strategies Fund (ACP) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
abrdn Income Credit Strategies Fund vs Inovio Pharmaceuticals Inc — how do they compare? abrdn Income Credit Strategies Fund trades at $5.22 (market cap $656.21M), while Inovio Pharmaceuticals Inc trades at $1.19 (market cap $99.55M). The key difference: abrdn Income Credit Strategies Fund is far larger — about 6.6× Inovio Pharmaceuticals Inc's market cap, and abrdn Income Credit Strategies Fund pays a 17.78% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| ACP | INO | |
|---|---|---|
Market Cap | $656.21M | $99.55M |
Sector | Financials | Health |
52-Week High | $5.98 | $2.87 |
52-Week Low | $5.01 | $1.05 |
Dividend Yield | 17.78% | — |
Enterprise Value | — | $70.56M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACP trades at $5.25, down 0.57% today, with a neutral technical signal. The stock shows a low P/B of 0.89 and a high net income margin of 95.51% for 2024, though revenue declined from $79M in 2024 to $42M in 2025. Recent news highlights dividend declarations and a Seeking Alpha downgrade citing distribution sustainability concerns. Cash flow from operations was negative $81.31M in 2024, offset by financing inflows.
Outlook is mixed: valuation appears modest with a P/E near 16, but declining revenue and negative operating cash flow pose risks. The 17% distribution rate faces sustainability questions, while technical indicators suggest limited near-term momentum. Investors should weigh income potential against fundamental weaknesses and high beta exposure.
INO trades at $1.21, down 2.02% today, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company shows minimal revenue of $65,340 (2025) with significant losses (-$84.95M net income), though recent earnings beats and FDA review of INO-3107 (PDUFA date October 30, 2026) provide catalysts. Analyst consensus is 53% buy, but multiple class action lawsuits pose legal risks.
Outlook hinges on FDA approval of INO-3107, which could drive upside, but high cash burn (-$21.54M net cash flow in 2025) and negative margins (-130,000% net income margin) underscore substantial operational risks. Investors face a binary event-driven opportunity with elevated volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About abrdn Income Credit Strategies Fund
abrdn Income Credit Strategies Fund is a diversified, closed-end investment management company. Its primary goal is to generate high current income, with capital appreciation as a secondary objective. The fund mainly invests in debt and loan instruments from issuers across various industries and regions.
Read more on ACP →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
